Acute insulin resistance following injury

Trends in Endocrinology and Metabolism

Volumn 20, Issue 9, 2009, Pages 429-435

  Li, Li ^a   Messina, Joseph L ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; METYRAPONE; MIFEPRISTONE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SOMATOMEDIN BINDING PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ACUTE DISEASE; BLEEDING; BURN; CLINICAL TRIAL; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG TARGETING; GLUCOSE METABOLISM; HORMONE INHIBITION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INCIDENCE; INFECTION; INSULIN RESISTANCE; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; SURGICAL INJURY; TISSUE SPECIFICITY;

ANIMALS; BURNS; CRITICAL ILLNESS; HEMORRHAGE; HUMANS; HYPERGLYCEMIA; INFECTION; INSULIN; INSULIN RESISTANCE; SEPSIS; WOUNDS AND INJURIES;

EID: 72049101882     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2009.06.004     Document Type: Review

References (76)

1. Van den Berghe G., et al. Intensive insulin therapy in the critically ill patients. N. Engl. J. Med. 345 (2001) 1359-1367
2. Thorell A., et al. Insulin resistance: a marker of surgical stress. Curr. Opin. Clin. Nutr. Metab.Care 2 (1999) 69-78
3. McCowen K.C., et al. Sustained endotoxemia leads to marked down-regulation of early steps in the insulin-signaling cascade. Crit. Care Med. 29 (2001) 839-846
4. Ma Y., et al. Hemorrhage induces the rapid development of hepatic insulin resistance. Am. J. Physiol. Gastrointest. Liver Physiol 284 (2003) G107-115
5. Ma Y., et al. Mechanisms of hemorrhage-induced hepatic insulin resistance: role of tumor necrosis factor-alpha. Endocrinology 145 (2004) 5168-5176
6. Xu J., et al. Trauma and hemorrhage-induced acute hepatic insulin resistance: dominant role of tumor necrosis factor (TNF)-alpha. Endocrinology 149 (2008) 2369-2382
7. Li L., et al. Tissue specific difference in the molecular mechanisms for the development of acute insulin resistance following injury. Endocrinology 150 (2009) 24-32
8. Thompson L.H., et al. Acute muscle-type specific insulin resistance following injury. Mol. Med. 11-12 (2008) 715-723
9. Simkova V., et al. Year in review 2006: critical care-multiple organ failure, sepsis, and shock. Crit. Care 11 (2007) 221-227
10. Vincent J.L., et al. Reducing mortality in sepsis: new directions. Crit. Care 6 Suppl 3 (2002) S1-18
11. Rivers E., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 345 (2001) 1368-1377
12. Bernard G.R., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344 (2001) 699-709
13. Finney S.J., et al. Glucose control and mortality in critically ill patients. JAMA 290 (2003) 2041-2047
14. Vincent J.L. Metabolic support in sepsis and multiple organ failure: more questions than answers. Crit. Care Med. 35 (2007) S436-S440
15. Herndon D.N., and Wernerman J. Metabolic support in sepsis and multiple organ failure. Crit. Care Med. 35 (2007) S435-S439
16. Van Cromphaut S.J., et al. Glucose metabolism and insulin resistance in sepsis. Curr. Pharm. Des. 14 (2008) 1887-1899
17. Desouza C., et al. Management of the insulin resistance syndrome. Curr. Diab. Rep. 1 (2001) 140-147
18. Kendall D.M., and Harmel A.P. The metabolic syndrome, type 2 diabetes, and cardiovascular disease: understanding the role of insulin resistance. Am. J. Manag. Care 8 (2002) S635-S653
19. Van den Berghe G., et al. Intensive insulin therapy in the medical ICU. N. Engl. J. Med. 354 (2006) 449-461
20. Krinsley J.S. Glycemic control, diabetic status, and mortality in a heterogeneous population of critically ill patients before and during the era of intensive glycemic management: six and one-half years experience at a university-affiliated community hospital. Semin. Thorac. Cardiovasc. Surg. 18 (2006) 317-325
21. Krinsley J.S. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin. Proc. 79 (2004) 992-1000
22. Finfer S., et al. Intensive versus conventional glucose control in critically ill patients. N. Engl. J. Med. 360 (2009) 1283-1297
23. Griesdale D.E., et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. Can Med. Assoc. J. 180 (2009) 821-827
24. Brunkhorst F.M., et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N. Engl. J. Med. 358 (2008) 125-139
25. Krinsley J.S. Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit. Care Med. 36 (2008) 3008-3013
26. Ng S.M., et al. Continuous insulin infusion in hyperglycaemic extremely-low- birth-weight neonates. Biol. Neonate. 87 (2005) 269-272
27. Beardsall K., et al. Early insulin therapy in very-low-birth-weight infants. N. Engl. J. Med. 359 (2008) 1873-1884
28. Nasraway Jr. S.A. Hyperglycemia during critical illness. JPEN J. Parenter Enteral Nutr 30 (2006) 254-258
29. Egi M., et al. Blood glucose concentration and outcome of critical illness: the impact of diabetes. Crit. Care Med. 36 (2008) 2249-2255
30. Arabi Y.M., et al. Intensive versus conventional insulin therapy: a randomized controlled trial in medical and surgical critically ill patients. Crit. Care Med. 36 (2008) 3190-3197
31. Fatourechi M.M., et al. Hypoglycemia with intensive insulin therapy. A systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J. Clin. Endocrinol. Metab. 94 (2008) 729-740
32. Krinsley J.S., and Grover A. Severe hypoglycemia in critically ill patients: risk factors and outcomes. Crit. Care Med. 35 (2007) 2262-2267
33. Vanhorebeek I., et al. Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. Lancet 365 (2005) 53-59
34. bdul-Ghani M.A., et al. Mitochondrial reactive oxygen species generation in obese non-diabetic and type 2 diabetic participants. Diabetologia 52 (2009) 574-582
35. Santangelo C., et al. Hepatocyte growth factor protects rat RINm5F cell line against free fatty acid-induced apoptosis by counteracting oxidative stress. J. Mol. Endocrinol. 38 (2007) 147-158
36. Stephens J.M., et al. Differential regulation of glucose transporter gene expression in adipose tissue or septic rats. Biochem. Biophys. Res. Commun. 183 (1992) 417-422
37. Virkamaki A., and Yki-Jarvinen H. Mechanisms of insulin resistance during acute endotoxemia. Endocrinology 134 (1994) 2072-2078
38. Hessman Y., and Thoren L. Glycogen storage in rat liver and skeletal muscle in thermal trauma. I. Effect of exogenous insulin. Acta. Chir. Scand. 141 (1975) 385-392
39. Nelson K.M., and Turinsky J. Effect of insulin on glucose and amino acid uptake by skeletal muscle following burn injury. Studies with 2-deoxyglucose and alpha-aminoisobutyric acid. JPEN J. Parenter. Enteral. Nutr. 6 (1982) 3-8
40. Cree M.G., et al. Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate. Ann. Surg. 245 (2007) 214-221
41. Cree M.G., et al. Role of fat metabolism in burn trauma-induced skeletal muscle insulin resistance. Crit. Care Med. 35 (2007) S476-S483
42. Ikezu T., et al. Analysis of thermal injury-induced insulin resistance in rodents. Implication of postreceptor mechanisms. J. Biol. Chem. 272 (1997) 25289-25295
43. Sugita H., et al. Burn injury impairs insulin-stimulated Akt/PKB activation in skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 288 (2005) E585-E591
44. White M.F. The insulin signalling system and the IRS proteins. Diabetologia 40, Suppl (1997) S2-17
45. Nakae J., and Accili D. The mechanism of insulin action. J. Pediatr. Endocrinol. Metab. 12 Suppl 3 (1999) 721-731
46. Cusi K., et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J. Clin. Invest. 105 (2000) 311-320
47. James D.E., et al. Heterogeneity of insulin action in individual muscles in vivo: euglycemic clamp studies in rats. Am. J. Physiol. 248 (1985) E567-E574
48. Mesotten D., et al. Regulation of insulin-like growth factor binding protein-1 during protracted critical illness. J. Clin. Endocrinol. Metab. 87 (2002) 5516-5523
49. Mesotten D., et al. Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin therapy. J. Clin. Endocrinol. Metab 89 (2004) 219-226
50. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46 (1997) 3-10
51. Yu C., et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 277 (2002) 50230-50236
52. Rui L., et al. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J. Biol. Chem. 277 (2002) 42394-42398
53. Slavin B.G., et al. Hormonal regulation of hormone-sensitive lipase activity and mRNA levels in isolated rat adipocytes. J. Lipid. Res 35 (1994) 1535-1541
54. Fasshauer M., et al. Insulin resistance-inducing cytokines differentially regulate SOCS mRNA expression via growth factor- and Jak/Stat-signaling pathways in 3T3-L1 adipocytes. J. Endocrinol. 181 (2004) 129-138
55. Krebs D.L., and Hilton D.J. SOCS proteins: negative regulators of cytokine signaling. Stem Cells 19 (2001) 378-387
56. Vaughan G.M., et al. Cortisol and corticotrophin in burned patients. J. Trauma 22 (1982) 263-273
57. Jurney T.H., et al. Spectrum of serum cortisol response to ACTH in ICU patients. Correlation with degree of illness and mortality. Chest 92 (1987) 292-295
58. Span L.F., et al. Adrenocortical function: an indicator of severity of disease and survival in chronic critically ill patients. Intensive Care Med. 18 (1992) 93-96
59. Phillips D.I., et al. Elevated plasma cortisol concentrations: a link between low birth weight and the insulin resistance syndrome?. J. Clin. Endocrinol. Metab 83 (1998) 757-760
60. Nosadini R., et al. Insulin resistance in Cushing's syndrome. J. Clin. Endocrinol. Metab 57 (1983) 529-536
61. Pagano G., et al. An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. J. Clin. Invest. 72 (1983) 1814-1820
62. Binnert C., et al. Dexamethasone-induced insulin resistance shows no gender difference in healthy humans. Diabetes. Metab. 30 (2004) 321-326
63. Ruzzin J., et al. Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor. Diabetologia 48 (2005) 2119-2130
64. Atkinson H.C., et al. Corticosteroids mediate fast feedback of the rat hypothalamic-pituitary-adrenal axis via the mineralocorticoid receptor. Am. J. Physiol. Endocrinol. Metab. 294 (2008) E1011-E1022
65. Hyde G.N., et al. Cortisol rapidly suppresses intracellular calcium and voltage-gated calcium channel activity in prolactin cells of the tilapia (Oreochromis mossambicus). Am. J. Physiol. Endocrinol. Metab. 286 (2004) E626-E633
66. Hotamisligil G.S., et al. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259 (1993) 87-91
67. Feinstein R., et al. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J. Biol. Chem. 268 (1993) 26055-26058
68. Kyriakis J.M., and Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81 (2001) 807-869
69. Baud V., and Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends. Cell. Biol. 11 (2001) 372-377
70. Hirosumi J., et al. A central role for JNK in obesity and insulin resistance. Nature 420 (2002) 333-336
71. Lin Y., et al. The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J. Biol. Chem. 280 (2005) 4617-4626
72. Eriksson J.W. Metabolic stress in insulin's target cells leads to ROS accumulation - a hypothetical common pathway causing insulin resistance. FEBS Lett. 581 (2007) 3734-3742
73. Kumashiro N., et al. Impact of oxidative stress and peroxisome proliferator-activated receptor gamma coactivator-1alpha in hepatic insulin resistance. Diabetes 57 (2008) 2083-2091
74. Furukawa S., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114 (2004) 1752-1761
75. Clement S., et al. The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 409 (2001) 92-97
76. Nakashima N., et al. The tumor suppressor PTEN negatively regulates insulin signaling in 3T3-L1 adipocytes. J. Biol. Chem. 275 (2000) 12889-12895